Intercos (ICOS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Q1 2026 net sales were €227.5 million, down 6.3% at constant FX and 9.3% reported year-over-year, mainly due to currency headwinds, reduced packaging sales, and a high comparison base from last year.
Adjusted EBITDA was €25 million (11% margin), down from €29.3 million (11.7% margin) in Q1 2025, reflecting lower fixed cost absorption and reduced volumes.
Cash generation was strong, with €7 million positive cash flow despite €25 million in share buybacks and €19 million in dividends; net debt improved to €119.7 million.
Order entry and intake remained robust in late 2025 and early 2026, supporting expectations for revenue growth in coming quarters.
CFO change announced, with interim appointment of COO as acting CFO; management team remains stable.
Financial highlights
Q1 sales declined 6.3% at constant FX and 9.3% reported; Make-up sales were €149.4 million (down 5.2%), Skincare €29.4 million (down 16.8%), Hair & Body €48.7 million (down 15.9%).
Adjusted EBITDA margin was 11%, down 66 bps year-over-year.
Net debt improved by €7.2 million year-over-year, with leverage at 0.79x.
Cash outflows included €25 million in share buybacks and €19 million in dividends.
Outlook and guidance
Net revenues for 2026 are expected to grow 5–6% versus 2025, supported by strong order intake and innovation.
Beauty market anticipated to grow 4–5% in 2026, with recovery in China and the US and Make-up expected to accelerate later in the year.
Guidance confirmed, with margins expected to improve as volumes recover and fixed cost absorption increases.
Innovation and geographic diversification are key strategic priorities.
Latest events from Intercos
- Record profitability and margin expansion achieved in 2025; growth expected in 2026.ICOS
Q4 20254 Mar 2026 - Adjusted EBITDA up 12.3% in 9M25, with Make-up driving growth and margin improvement.ICOS
Q3 20253 Feb 2026 - Record Q2 sales and EBITDA drive recovery; FY24 growth guidance and expansion reaffirmed.ICOS
Q2 20242 Feb 2026 - Q3 sales and EBITDA up over 12%, driven by Asia and EMEA, with margin pressure ongoing.ICOS
Q3 202416 Jan 2026 - 2024 sales up 8% to €1.06bn, EBITDA up 4.3%, and 2025 growth guided at 5–7%.ICOS
Q4 20242 Dec 2025 - Q1 2025 sales up 13.4% and EBITDA up 40.6%, driven by Make-up and multinational demand.ICOS
Q1 202526 Nov 2025 - Strong H1 sales and margin gains led by Make-up, despite currency and Hair & Body headwinds.ICOS
Q2 202523 Nov 2025